MILLGATE HEALTHCARE PARTNERSHIP
ANN STREET, DENTON, MANCHESTER
HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 45 | 53 | 84.9% | |
| HF 4 | 2011 | 49 | 56 | 87.5% | |
| HF 4 | 2012 | 48 | 51 | 94.1% | |
| HF 4 | 2013 | 50 | 51 | 98.0% | |
| HF004 | 2014 | 16 | 16 | 100.0% | |
| HF004 | 2015 | 15 | 15 | 100.0% | |
| HF004 | 2016 | 20 | 20 | 100.0% | |
| HF004 | 2017 | 19 | 19 | 100.0% | |
| HF004 | 2018 | 59 | 62 | 95.2% | |
| HF004 | 2019 | 73 | 82 | 89.0% | |
| HF004 | 2020 | 85 | 98 | 86.7% | |
| HF006 | 2021 | 89 | 97 | 91.8% | |
| HF006 | 2022 | 88 | 95 | 92.6% | |
| HF006 | 2023 | 88 | 91 | 96.7% |
